Resources

15 Resources for

vytorin

  • Subscribe to this listing via:
  • RSS
  • Email

BNET Resources

Schering-Plough Now in the Feds' Crosshairs
Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
Tags: ENHANCE Trial, Schering, Schering-Plough Corp., trial result, Vytorin, Zocor, Merck & Co. Inc.
Discussion threads 2008-07-10
Is Merck Hanging Schering Out to Dry on Vytorin?
Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
Tags: ENHANCE Trial, Merck & Co. Inc., Schering, Vytorin, Zocor
Discussion threads 2008-07-07
How Pharma Stacks the Deck with Medical Journals
How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
Tags: ENHANCE Trial, Schering, trial result, Vytorin, Zocor
Discussion threads 2008-06-18
Vytorin Update: Big Pharma Strikes Back
The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
Tags: Sales, E-mail, Sales Strategy, Vytorin, Trial, Pharmaceutical Company, Merck & Co. Inc., Online Communications, David P. Hamilton
Blog posts 2008-04-03
Marketing Trumps Science in Vytorin Scandal
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
Tags: Online Communications, Marketing, E-mail, Marketing Research, Schering, Zetia, Vytorin, Drug, Merck & Co. Inc., David P. Hamilton
Blog posts 2008-04-01
FDA Approves New Label for VYTORIN®
New Label Includes Data Demonstrating VYTORIN Lowered LDL "Bad" Cholesterol more than Crestor at all Doses Compared
Tags: FDA, Vytorin
Research articles 2006-10-05
Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN® Superior to Lipitor in Reducing LDL "Bad" Cholesterol in Patients with Type II Diabetes at the Dose Comparisons Studied
Greater LDL Cholesterol Reduction with VYTORIN Compared to Lipitor Resulted in Greater LDL Cholesterol Goal Attainment
Tags: Lipitor, Mayo Clinic, patient, Vytorin
Research articles 2006-12-21
Generic competition threatens AstraZeneca.
The US launch this month of cholesterol-lowering drug Vytorin could mean thinner pickings for AstraZeneca's product, Crestor. The US launch this month of cholesterol-lowering drug Vytorin could mean thinner pickings for AstraZeneca's product, Crestor.
Tags: AstraZeneca Plc., Vytorin
Research articles 2004-08-20
Merck and Schering-Plough's statin combo hits pharmacies
THE STATIN category got a new addition last month following FDA approval of Merck and Schering-Plough's Vytorin (ezetimibe/simvastatin), which combines Merck's Zocor and Zetia from Schering-Plough. Vytorin was expected in pharmacies by Labor Day.
Tags: Merck & Co. Inc., Schering-Plough Corp., Vytorin
Research articles 2004-09-01
Schering-Plough Now in the Feds' Crosshairs
The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries.  Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...
Tags: SEC, Merck & Co. Inc., Schering-Plough Corp., Attorney, Vytorin, Sales Strategy, Healthcare, Sales Force Management, Sales, David P. Hamilton
Blog posts 2008-05-07
Is Merck Hanging Schering Out to Dry on Vytorin?
A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin. Vytorin, of course, is a combination...
Tags: Merck & Co. Inc., Cholesterol, Schering, Vytorin, David P. Hamilton
Blog posts 2008-04-23
Merck, Schering Unable to Stop Digging in Vytorin Mess
As an example of how not to handle a corporate crisis, it's hard to beat the growing scandal over Vytorin. That's the blockbuster anti-cholesterol drug whose clinical-trial data Merck and Schering-Plough sat on for a year or two after it showed that Vytorin was apparently no better than a...
Tags: Merck & Co. Inc., Vytorin, House Committee, Sales Strategy, E-mail, Healthcare, Sales, Online Communications, David P. Hamilton
Blog posts 2008-04-14
Vytorin Update: Big Pharma Strikes Back
The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
Tags: Merck & Co. Inc., Pharmaceutical Company, Trial, Vytorin, Sales Strategy, E-mail, Sales, Online Communications, David P. Hamilton
Blog posts 2008-04-03
Marketing Trumps Science in Vytorin Scandal
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
Tags: Merck & Co. Inc., Drug, Vytorin, Zetia, Schering, E-mail, Marketing Research, Online Communications, Marketing, David P. Hamilton
Blog posts 2008-04-01
Schering-Plough's Hassan Made Stock Gains as Price Tumbled and Layoffs Grew
About 1,000 sales reps are being let go from Schering-Plough this week. That's on top of 60 animal health reps also being fired. Roughly 5,500 employees in general are being axed in Schering-Plough's cost-cutting drive. If you're one of those people, comfort yourself with the fact that...
Tags: Layoff, Stock, Schering-Plough Corp., Fred Hassan, SGP, Vytorin, Investment, Finance, Jim Edwards
Blog posts 2008-09-19

Additional Resources

African Americans Should Not Stop Taking Vytorin or Zetia Without Consulting Their Healthcare Providers
To: MEDICAL EDITORS Contact: Keith Ferdinand, MD, +1-404-201-6632 ATLANTA, Jan. 24 /PRNewswire/ -- The recent release of the ENHANCE study of Vytorin and Zetia has drawn considerable media attention, but stopping cholesterol medications based on this study alone is not appropriate. The next step for any concerned patient with...
Tags: ABC Inc., Benefits, cholesterol, consulting, HEALTHCARE, medication, SOFTWARE
Research articles 2008-01-24
Merck/Schering Vytorin Settlement Shows New Trend: Government Control of Drug Ads
In Merck and Schering-Plough's settlement with the state attorneys general over Vytorin contains a set of provisions that are fast becoming the new normal for large drug companies: Government control of drug advertising, including pre-approval of ads and years-long compliance reviews. by Jim Edwards
Tags: Advertisement, Compliance, Settlement, Government, Litigation, Vertical Industries, Business Operations, Jim Edwards
Blog posts 2009-07-18
"Informant" Names Schering Execs Who Allegedly Knew Vytorin/Enhance Trial Was a Bust, Suit Claims
An amended lawsuit filed over the Schering-Plough pension plan alleges that executives at the company suspected as early as 2005 that the Enhance Vytorin trial was a bust. Citing a "confidential informant," it also names names. by Jim Edwards
Tags: Bust, Informant, Benefits, Payroll Solutions, Human Resources, Jim Edwards
Blog posts 2009-10-12
Fred Hassan, Schering's $30 Million Man
Schering-Plough has had a fairly miserable year so far, thanks to its apparent efforts to keep bad scientific news about the cholesterol pill Vytorin out of the public eye. CEO Fred Hassan, however, is still living off last year's glory -- even if it might well have been far less...
Tags: Shareholder, Compensation, Performance, Stock, Schering-Plough Corp., Schering, Benefits, Performance Management, Investment, Human Resources, Workforce Management, Finance, David P. Hamilton
Blog posts 2008-04-24
Should We Be Surprised That Schering-Plough Execs Are "Surprised" By Sugammadex Rejection?
Yet another setback for Schering-Plough seems to have taken top management by surprise. Schering’s shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia-recovery drug would not be approved by the FDA. In a statement, Schering VP Thomas Koestler said he was “surprised...
Tags: Revenue, FDA, Schering-Plough Corp., Diversity, Schering, NuvaRing, Federal Government, Operational Accounting, Government, Finance, Jim Edwards
Blog posts 2008-08-01
  • << Previous
  • page 1 of 1
  • Next >>
advertisement
advertisement
Click Here